- All sections
- C - Chemistrymetallurgy
- C07K - Peptides
- C07K 14/74 - Major histocompatibility complex [MHC]
Patent holdings for IPC class C07K 14/74
Total number of patents in this class: 1890
10-year publication summary
|
94
|
105
|
124
|
188
|
250
|
247
|
296
|
260
|
206
|
77
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Immatics Biotechnologies GmbH | 1152 |
524 |
| Cue Biopharma, Inc. | 186 |
95 |
| Regeneron Pharmaceuticals, Inc. | 4223 |
56 |
| CRISPR Therapeutics AG | 361 |
54 |
| University Health Network | 1031 |
29 |
| 10X Genomics, Inc. | 1184 |
23 |
| Board of Regents, The University of Texas System | 5751 |
18 |
| The Regents of the University of California | 19812 |
17 |
| Imcyse SA | 73 |
15 |
| Sangamo Therapeutics, Inc. | 415 |
15 |
| Ecole Polytechnique Federale de Lausanne (epfl) | 1526 |
14 |
| Oregon Health & Science University | 762 |
14 |
| Universite de Montreal | 343 |
13 |
| Inscripta, Inc., FORMERLY Muse Biotechnology, Inc. | 310 |
13 |
| Sana Biotechnology, Inc. | 152 |
13 |
| Xyphos Biosciences Inc. | 34 |
12 |
| Immunocore Limited | 212 |
11 |
| UTi Limited Partnership | 449 |
11 |
| Albert Einstein College of Medicine, Inc. | 573 |
9 |
| Dana-Farber Cancer Institute, Inc. | 2553 |
9 |
| Other owners | 925 |